
Exact Cure develops a disruptive software solution that utilizes Artificial Intelligence to create a Digital Twin for personalized medication management. This innovative platform simulates the effectiveness and interactions of drugs based on individual patient characteristics, helping to prevent underdoses, overdoses, and drug-drug interactions. With a strong technical and business foundation, the company aims to lead in personalized bio-modeling, empowering patients and healthcare professionals with tailored medication insights. Exact Cure's ambition is to revolutionize how medications are prescribed and monitored, positioning itself as a key player in the healthcare technology market.

Exact Cure develops a disruptive software solution that utilizes Artificial Intelligence to create a Digital Twin for personalized medication management. This innovative platform simulates the effectiveness and interactions of drugs based on individual patient characteristics, helping to prevent underdoses, overdoses, and drug-drug interactions. With a strong technical and business foundation, the company aims to lead in personalized bio-modeling, empowering patients and healthcare professionals with tailored medication insights. Exact Cure's ambition is to revolutionize how medications are prescribed and monitored, positioning itself as a key player in the healthcare technology market.
What they do: Create patient-specific 'digital twin' simulations to model drug effects, dosing, and drug–drug interactions
Founded: 2017
Headquarters: Nice, Provence-Alpes-Côte d'Azur, France
Funding: Seed round led by OneRagtime (Nov 14, 2019); reported total funding figures vary
Team size (public profile): About 6 employees
Medication safety, personalized dosing, and drug–drug interaction prediction
2017
Biotechnology
Public profiles report a Seed round announced Nov 14, 2019; other profiles report additional grants and amounts but figures are not consistently specified.
“OneRagtime led the Seed round”